E A Olsen

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Evaluation and treatment of male and female pattern hair loss
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Acad Dermatol 52:301-11. 2005
  2. ncbi Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Acad Dermatol 67:379-86. 2012
  3. ncbi Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    E Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 19:376-88. 2001
  4. ncbi Central hair loss in African American women: incidence and potential risk factors
    Elise A Olsen
    Duke University Medical Center, Durham, NC, USA
    J Am Acad Dermatol 64:245-52. 2011
  5. ncbi Update on cicatricial alopecia
    E Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Investig Dermatol Symp Proc 8:18-9. 2003
  6. ncbi Interferon in the treatment of cutaneous T-cell lymphoma
    Elise A Olsen
    Division of Dermatology, CTCL Clinic and Research Center, Duke University, Durham, North Carolina 27710, USA
    Dermatol Ther 16:311-21. 2003
  7. ncbi Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca
    Elise Olsen
    Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC 27516, USA
    Blood 110:1713-22. 2007
  8. ncbi Vascular based non conventional dye laser treatment for basal cell carcinoma
    P Campolmi
    Department of Dermatological Science, University of Florence, Florence, Italy
    Dermatol Ther 21:402-5. 2008
  9. ncbi Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation
    Elise A Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Am Acad Dermatol 51:440-7. 2004
  10. ncbi Central scalp alopecia photographic scale in African American women
    E A Olsen
    Division of Dermatology and Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Dermatol Ther 21:264-7. 2008

Detail Information

Publications42

  1. ncbi Evaluation and treatment of male and female pattern hair loss
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Acad Dermatol 52:301-11. 2005
  2. ncbi Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Acad Dermatol 67:379-86. 2012
    ..Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years...
  3. ncbi Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    E Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 19:376-88. 2001
    ....
  4. ncbi Central hair loss in African American women: incidence and potential risk factors
    Elise A Olsen
    Duke University Medical Center, Durham, NC, USA
    J Am Acad Dermatol 64:245-52. 2011
    ..Although central scalp hair loss is a common problem in African American women, data on etiology or incidence are limited...
  5. ncbi Update on cicatricial alopecia
    E Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Investig Dermatol Symp Proc 8:18-9. 2003
    ....
  6. ncbi Interferon in the treatment of cutaneous T-cell lymphoma
    Elise A Olsen
    Division of Dermatology, CTCL Clinic and Research Center, Duke University, Durham, North Carolina 27710, USA
    Dermatol Ther 16:311-21. 2003
    ..An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper...
  7. ncbi Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca
    Elise Olsen
    Department of Medicine, Divisions of Dermatology and Oncology, Duke University Medical Center, Durham, NC 27516, USA
    Blood 110:1713-22. 2007
    ..The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions...
  8. ncbi Vascular based non conventional dye laser treatment for basal cell carcinoma
    P Campolmi
    Department of Dermatological Science, University of Florence, Florence, Italy
    Dermatol Ther 21:402-5. 2008
    ..A complete response was obtained in 16 patients out of 20. Three recurrences and one no response was observed during the study. Pulse dye laser is effective and safe in the treatment of superficial basal cell carcinoma...
  9. ncbi Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation
    Elise A Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Am Acad Dermatol 51:440-7. 2004
  10. ncbi Central scalp alopecia photographic scale in African American women
    E A Olsen
    Division of Dermatology and Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Dermatol Ther 21:264-7. 2008
    ....
  11. ncbi The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Acad Dermatol 55:1014-23. 2006
    ..Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor...
  12. ncbi A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina 27516, USA
    J Am Acad Dermatol 57:767-74. 2007
    ..An alternative to currently marketed topical minoxidil solutions is desirable...
  13. ncbi Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss
    Elise A Olsen
    Division of Dermatology, Duke University Medical Center, Box 3294, Durham, NC 27710, USA
    J Am Acad Dermatol 48:253-62. 2003
  14. ncbi Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    Elise A Olsen
    Duke University, Durham, NC, USA
    J Clin Oncol 25:3109-15. 2007
    ....
  15. ncbi Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
    Elise A Olsen
    Duke University Medical Center, Durham, NC, USA
    J Am Acad Dermatol 64:352-404. 2011
    ..Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted...
  16. ncbi Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the E
    Elise A Olsen
    Duke University Medical Center, Box 3294, Durham, NC 27710, USA
    J Clin Oncol 29:2598-607. 2011
    ..These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS...
  17. ncbi The presence of loose anagen hairs obtained by hair pull in the normal population
    E A Olsen
    Duke University Medical Center, Durham, North Carolina 27710, USA
    J Investig Dermatol Symp Proc 4:258-60. 1999
    ..Correlation of these findings with the various hair disorder phenotypes currently termed Loose Anagen Syndrome will be important...
  18. ncbi Investigative guidelines for alopecia areata
    Elise A Olsen
    Department of Dermatology and Medicine Oncology, Duke University Medical Center, Durham, North Carolina 27110, USA
    Dermatol Ther 24:311-9. 2011
    ..Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed...
  19. ncbi Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective
    Elise A Olsen
    Division of Dermatology, Department of Medicine Duke University Medical Center, Durham, North Carolina, USA
    J Investig Dermatol Symp Proc 10:217-21. 2005
    ..The potential relationship of these conditions as well as frontal fibrosing alopecia and central centrifugal cicatricial alopecia, two other conditions of permanent hair loss seen primary in women, is discussed...
  20. ncbi Pityriasis amiantacea: a report of two cases in adults
    M S Bettencourt
    Division of Dermatology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cutis 64:187-9. 1999
    ..It is most often associated with an underlying primary dermatosis. We describe two adult patients who did not present with concomitant scalp or cutaneous diseases...
  21. ncbi Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin)
    A P Dang-Vu
    Division of Dermatology, Duke University Medical Center, Durham, NC 27710
    J Am Acad Dermatol 19:692-8. 1988
    ..Low-dose 2'-deoxycoformycin appears to be safe but may be an insufficiently intensive regimen to treat refractory cutaneous T cell lymphoma. With proper biochemical monitoring, higher doses may be both safe and more effective...
  22. ncbi A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
    Elise A Olsen
    Duke Dermatopharmacology Study Center, Durham, North Carolina, USA
    J Am Acad Dermatol 47:377-85. 2002
    ..Psychosocial perceptions of hair loss in men with AGA were also improved. Topical minoxidil (5% and 2%) was well tolerated by the men in this trial without evidence of systemic effects...
  23. ncbi My hair is thinning on the top of my head. What treatments are available for hair loss in women?
    Elise A Olsen
    Duke University Medical Center, USA
    Health News 8:12. 2002
  24. ncbi Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Acad Dermatol 48:103-10. 2003
  25. ncbi Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis
    S A Grevelink
    Department of Medicine, Duke University Medical Center, Durham, NC 27710
    J Am Acad Dermatol 27:182-8. 1992
    ..CONCLUSION: The results indicate that Stokogard, Hollister Moisture Barrier, and Hydropel are effective in the prevention of Toxicodendron dermatitis...
  26. ncbi A controlled trial of clobetasol propionate ointment 0.05% in the treatment of experimentally induced Rhus dermatitis
    H J Vernon
    Department of Medicine, Duke University Medical Center, Durham, NC 27710
    J Am Acad Dermatol 23:829-32. 1990
    ..On the basis of this experimental model, clobetasol propionate ointment 0.05% may be effective therapy for naturally occurring Rhus dermatitis...
  27. ncbi Keratosis follicularis spinulosa decalvans in a family
    Jane S Bellet
    Department of Medicine, Division of Dermatology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Acad Dermatol 58:499-502. 2008
    ..Multiple topical and systemic treatments have been unsuccessful in this patient, attesting to the treatment refractoriness typically seen in KFSD...
  28. ncbi Female pattern hair loss
    Elise A Olsen
    Duke University Medical Center, Durham, NC 27710, USA
    J Am Acad Dermatol 47:795. 2002
  29. ncbi Topical 5-fluorouracil is ineffective in the treatment of extensive alopecia areata
    Andrew L Kaplan
    Duke University Medical Center, Durham, North Carolina, USA
    J Am Acad Dermatol 50:941-3. 2004
    ..Based on these results, we cannot recommend the use of topical 5-FU for treatment of alopecia areata without further evidence of therapeutic benefit...
  30. ncbi Defining early mycosis fungoides
    Nicola Pimpinelli
    Department of Dermatological Sciences, University of Florence, Florence, Italy
    J Am Acad Dermatol 53:1053-63. 2005
    ....
  31. ncbi Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups
    Elise A Olsen
    Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Acad Dermatol 63:991-9. 2010
    ..The literature suggests that iron deficiency (ID) may play a role in female pattern hair loss (FPHL) or in chronic telogen effluvium (CTE)...
  32. ncbi Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss
    David A Whiting
    Dallas Associated Dermatologists, 3600 Gaston Avenue, 1051 LB76, TX 75246, USA
    Eur J Dermatol 13:150-60. 2003
    ..Improvement was evident by 6 months of treatment and continued through 24 months. Treatment with finasteride 1 mg was generally well tolerated...
  33. ncbi Short anagen syndrome
    Richard J Antaya
    Department of Dermatology, Yale University, New Haven, Connecticut 06520 8059, USA
    J Am Acad Dermatol 53:S130-4. 2005
    ....
  34. ncbi Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach
    Steven M Horwitz
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 6:436-42. 2008
    ..Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation...
  35. ncbi Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)
    Madeleine Duvic
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 2:222-8. 2002
    ..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
  36. ncbi Subcutaneous efalizumab is not effective in the treatment of alopecia areata
    Vera H Price
    Department of Dermatology, University of California, San Francisco, California, USA
    J Am Acad Dermatol 58:395-402. 2008
    ..Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis...
  37. ncbi TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Resear
    Youn H Kim
    Department of Dermatology, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
    Blood 110:479-84. 2007
    ..Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide...
  38. ncbi Central centrifugal cicatricial alopecia
    David A Whiting
    Department of Dermatology and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75246, USA
    Dermatol Ther 21:268-78. 2008
    ..Current research into the etiology of this disorder will help to foster much-needed clinical trials of therapeutic agents...
  39. ncbi Occupational alopecia or alopecia areata?
    Antonella Tosti
    J Am Acad Dermatol 47:636-7. 2002
  40. ncbi Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2
    Alain H Rook
    Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 17:1435-48, ix. 2003
    ....
  41. ncbi Iron deficiency and hair loss: the jury is still out
    Elise A Olsen
    J Am Acad Dermatol 54:903-6. 2006
  42. ncbi Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008